Literature DB >> 1899488

A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

V M Lee1, B J Balin, L Otvos, J Q Trojanowski.   

Abstract

Putative Alzheimer disease (AD)-specific proteins (A68) were purified to homogeneity and shown to be major subunits of one form of paired helical filaments (PHFs). The amino acid sequence and immunological data indicate that the backbone of A68 is indistinguishable from that of the protein tau (tau), but A68 could be distinguished from normal human tau by the degree to which A68 was phosphorylated and by the specific residues in A68 that served as phosphate acceptors. The larger apparent relative molecular mass (Mr) of A68, compared to normal human tau, was attributed to abnormal phosphorylation of A68 because enzymatic dephosphorylation of A68 reduced its Mr to close to that of normal tau. Moreover, the LysSerProVal motif in normal human tau appeared to be an abnormal phosphorylation site in A68 because the Ser in this motif was a phosphate acceptor site in A68, but not in normal human tau. Thus, the major subunits of a class of PHFs are A68 proteins and the excessive or inappropriate phosphorylation of normal tau may change its apparent Mr, thus transforming tau into A68.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899488     DOI: 10.1126/science.1899488

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  366 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue binding phosphatases.

Authors:  L Y Cheng; J Z Wang; C X Gong; J J Pei; T Zaidi; I Grundke-Iqbal; K Iqbal
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

Review 3.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

4.  Rapid induction of intraneuronal neurofibrillary tangles in apolipoprotein E-deficient mice.

Authors:  X Bi; A P Yong; J Zhou; C E Ribak; G Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 5.  Neurotoxic and synaptic effects of okadaic acid, an inhibitor of protein phosphatases.

Authors:  R Tapia; F Peña; C Arias
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

Review 6.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

7.  Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

Authors:  E B Mukaetova-Ladinska; F Garcia-Siera; J Hurt; H J Gertz; J H Xuereb; R Hills; C Brayne; F A Huppert; E S Paykel; M McGee; R Jakes; W G Honer; C R Harrington; C M Wischik
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

8.  Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons.

Authors:  S E Merrick; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

9.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

10.  Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APPswe/PS1dE9 Double Transgenic Mice Brains.

Authors:  Ji Zhang; Suqing Wang; Wei Huang; David A Bennett; Dennis W Dickson; Dengshun Wang; Rui Wang
Journal:  Mol Neurobiol       Date:  2015-09-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.